What the research found

In healthy people, the pancreas doesn't just react to rising blood glucose—it anticipates it. Insulin secretion peaks slightly before glucose levels spike after eating, guided by early hormonal signals (particularly GLP-1) that arrive a few minutes ahead of the glucose wave. This anticipatory timing appears to smooth out blood sugar swings.

In people with obesity and prediabetes, this coordination breaks down. GLP-1 arrives later and fades earlier, and insulin secretion follows the same delayed pattern. The result is a mismatch: insulin arrives too late to blunt the initial glucose spike, leading to prolonged elevation of blood sugar after meals.

When semaglutide (a GLP-1 receptor agonist) was given to these individuals, it did increase overall insulin output and reduce hyperglycemia—but it appeared to eliminate the anticipatory mechanism entirely. Insulin and glucose levels moved in sync rather than with glucose leading, which introduced the opposite problem: insulin now outlasted the glucose spike, causing blood sugar to drop lower than normal afterward.

Why it matters for you

If you're tracking fasting glucose, HbA1c, or postprandial glucose responses, this work suggests the timing of insulin secretion relative to eating matters as much as the absolute amount. Someone with normal fasting glucose but blunted anticipatory insulin might still experience larger postprandial swings—the kind that degrade energy, stress metabolic flexibility, and accelerate fatigue during training.

For users on GLP-1 therapy (semaglutide, tirzepatide), this hints at a trade-off worth monitoring. Yes, you'll lower average glucose and hyperglycemia. But watch your continuous glucose monitor (if you use one) for reactive hypoglycemia or delayed glucose nadirs hours after eating. That's not a sign the drug isn't working; it's a sign the normal anticipatory system has been overridden.

If you're optimizing without pharmacology—via training timing, meal composition, or sleep—the implication is that preserving hormonal coordination matters. Meals that trigger gradual, modest GLP-1 release (slower carbs, protein, fiber) may allow your pancreas to keep its natural rhythm intact better than high-glycemic loads that break it.

Caveats

• Observational in structure: This is a comparison of profiles across groups, not a randomized intervention testing causality
• Limited mechanistic detail: The study identifies that anticipatory secretion breaks down in obesity/prediabetes, but not exhaustively why
• Semaglutide finding is preliminary: The claim that semaglutide abolishes anticipatory secretion needs replication and may depend on dose, timing of administration, or individual factors
• No data on long-term outcomes: We don't know whether the loss of anticipatory timing on GLP-1 therapy translates to worse glycemic control, hypoglycemia risk, or clinical harm over months to years